31 July 2024 - The MSAC Secretariat has published a list of applications scheduled to be considered by the MSAC on 28-29 November 2024.

The agenda currently has 5 items. Applications of note include:

1734 – Intravascular lithotripsy for the treatment of moderately or severely calcified peripheral artery disease

1760 - DPYD genotyping to predict fluoropyrimidine-induced toxicity

1761 - Faecal calprotectin for the monitoring of disease activity in patients with inflammatory bowel disease

1766 – Genetic testing to detect AKT-pathway alterations in patients with hormone receptor-positive, HER2-negative advanced breast cancer, to determine eligibility for PBS subsidised capivasertib treatment

1775 – Newborn bloodspot screening for mucopolysaccharidosis type 1

Read MSAC agenda